Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;82(8):911-916.
doi: 10.1002/pros.24335. Epub 2022 Mar 16.

Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer

Per-Olof Lundgren  1 , Bernhard Tribukait  2 , Anders Kjellman  1 , Ulf Norming  3 , Kiran Jagarlmudi  4   5 , Ove Gustafsson  1
Affiliations

Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer

Per-Olof Lundgren et al. Prostate. 2022 Jun.

Abstract

Background: Thymidine kinase 1 (TK1) recycles DNA before cell division. We do not know if baseline blood concentrations of TK1 predict death in prostate cancer within 30 years. Our objective is to determine if there is an association between baseline levels of TK1 and future prostate cancer-specific mortality.

Methods: With a "proof of concept" approach, we performed a nested case-control study among 1782 individuals screened for prostate cancer between 1988 and 1989. The concentration of TK1 was measured in frozen serum from 330 men, 36 of whom have died of prostate cancer. The primary endpoint was prostate cancer-specific mortality and outcomes after 30 years were analyzed using logistic regression modeling odds ratios (Ors).

Results: The estimated OR (adjusted for age) for dying from prostate cancer among the men who had a TK1 value in the upper tertile was 2.39 (95% confidence interval 1.02-5.63). The corresponding OR, regardless of the cause of death, was 2.81 (1.24-6.34).

Conclusions: High levels of TK1 predicts death in prostate cancer within 30 years of follow-up.

Keywords: prognosis; prostate cancer; thymidine kinase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier estimates of prostate cancer‐specific survival by baseline level of thymidine kinase 1 [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
Kaplan–Meier estimates of prostate cancer incidence by baseline level of Thymidine kinase 1 [Color figure can be viewed at wileyonlinelibrary.com]
Figure 3
Figure 3
Scatterplot of baseline thymidine kinase 1 and time to diagnosis
See this image and copyright information in PMC

References

    1. van der Eijk P. Hippocrates in context. Papers read at: XIth International Hippocrates Colloquium, University of Newcastle upon Tyne, 27–31 August 2002. Leiden; Boston: Brill; 2005. - PubMed
    1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969‐974. - PubMed
    1. Grönberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population‐based diagnostic study. Lancet Oncol. 2015;16(16):1667‐1676. - PubMed
    1. Wintersberger E. Regulation and biological function of thymidine kinase. Biochem Soc T. 1997;25(1):303‐308. - PubMed
    1. Munch‐Petersen B. Enzymatic regulation of cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2: a mini review. Nucleosides Nucleotides Nucleic Acids. 2010;29(4‐6):363‐369. - PubMed

Publication types